SCHEMBL560116

SCHEMBL560116

Nc1ncc(Oc2cccc(Cl)c2)nc1-c1nc2ccccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
ATR Q13535 13/20 0.52
AR P10275 1/20 0.45
MAP4K4 O95819 1/20 0.45
PRKDC P78527 1/20 0.44
ATM Q13315 1/20 0.44
PDPK1 O15530 1/20 0.44
CDK1 P06493 1/20 0.44
CDK2 P24941 1/20 0.44
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
CHEK2 O96017 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559766 0.87 ATR (0.63) ATRPRKDCATMPDPK1CDK1
SCHEMBL560756 0.87 ATR (0.52) ATRPRKDCATMPDPK1CDK1
SCHEMBL560535 0.87 ATR (0.52) CYP1A2CYP2C9CYP2C19ATRAR
SCHEMBL560088 0.84 ATR (0.59) ATRMAP4K4PRKDCATMPDPK1
SCHEMBL560058 0.82 ATR (0.64) ATRMAP4K4PRKDCATMPDPK1
SCHEMBL560151 0.80 KMT2A (0.56) ATRALDH1A1HPGDSMN1; SMN2NPSR1
SCHEMBL10165965 0.78 ATR (0.52) ATRMAP4K4CHEK2ALDH1A1HPGD
SCHEMBL560062 0.78 ATR (0.49) ATRCHEK2ALDH1A1HPGDSMN1; SMN2
SCHEMBL559939 0.77 ATR (0.53) ATRPRKDCATMPDPK1CDK1
SCHEMBL560098 0.77 ATR (0.53) ATRATMCHEK2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 CYP1A2 3615/4885CYP2C9 4702/4885CYP2C19 4373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.